GILD:NASDAQ
Gilead Sciences, Inc
$144.92
arrow_downward
-0.50%(-0.74) 1D
Sep 10, 1:19:31 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GILD...
Open
$145.07
High
$145.91
Low
$143.67
Mkt. cap
179.69B
Avg. vol.
6.18M
Volume
1.41M
Dividend
2.26%
Quarterly dividend
$0.82
Ex-dividend date
Sep 15, 2026
52-wk high
$157.27
52-wk low
$108.46
EPS
-$2.66
Beta
0.34
Shares outstanding
1.24B
No. of employees
17K
Open
$145.07
High
$145.91
Low
$143.67
Mkt. cap
179.69B
Avg. vol.
6.18M
Volume
1.41M
Dividend
2.26%
Quarterly dividend
$0.82
Ex-dividend date
Sep 15, 2026
52-wk high
$157.27
52-wk low
$108.46
EPS
-$2.66
Beta
0.34
Shares outstanding
1.24B
No. of employees
17K
News stories
From web sources and news partners
GuruFocus
·
29 minutes ago
GILD Maintained by HSBC -- Price Target Raised to $175
MarketBeat
·
3 hours ago
HSBC Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price
Zacks
·
3 hours ago
Here's Why You Should Add NRIX Stock to Your Portfolio Now
Investing.com Canada
·
22 hours ago
Gilead at wells fargo healthcare conference: diversification deepens By Investing.com
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17K
FoundedJun 22, 1987
HeadquartersFoster City, California, United States
SectorBiotechnology
Websitegilead.com